MARKET

TAK

TAK

Takeda Pharma
NYSE

Real-time Quotes | Nasdaq Last Sale

14.10
-0.09
-0.63%
After Hours: 14.20 +0.1 +0.71% 19:48 10/15 EDT
OPEN
14.13
PREV CLOSE
14.19
HIGH
14.17
LOW
14.02
VOLUME
4.04M
TURNOVER
--
52 WEEK HIGH
19.97
52 WEEK LOW
14.02
MARKET CAP
44.62B
P/E (TTM)
11.44
1D
5D
1M
3M
1Y
5Y
Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
Zacks.com · 2d ago
FNY Investment Advisers, LLC Buys Alphabet Inc, Ardagh Group SA, BP PLC, Sells Soaring Eagle ...
GuruFocus News · 3d ago
BRIEF-Immusoft Signs Research Collaboration And License Option Agreement With Takeda Pharmaceutical Co Ltd
reuters.com · 3d ago
BioLife Plasma Services Announces Expansion of Plasma Donation Centers into Massachusetts
WORCESTER, Mass., October 13, 2021--BioLife Plasma Services announces new center opening in Worcester, MA to support an urgent need for plasma donations.
Business Wire · 3d ago
BRIEF-Takeda Says FDA Advisory Committee Recommends Use Of Investigational Drug Maribavir
reuters.com · 10/07 22:21
Morgan Stanley Downgrades Takeda Pharmaceutical to Equal-Weight
Morgan Stanley downgrades Takeda Pharmaceutical (NYSE:TAK) from Overweight to Equal-Weight.
Benzinga · 10/07 09:09
Hot Stocks: EV stocks fall; VLCN pops in debut; IGT sets high; TAK suspends trials; short-seller targets DNA
The major averages rallied late in Wednesday's trading to close the session higher. However, not every sector managed to pull out of negative territory. Electric vehicle stocks largely remained underwater,
Seekingalpha · 10/06 21:22
The Petri Dish: Takeda taps Selecta for gene therapy, BICO makes another buy
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.
American City Business Journals · 10/06 20:59
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TAK. Analyze the recent business situations of Takeda Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TAK stock price target is 18.50 with a high estimate of 20.59 and a low estimate of 17.26.
High20.59
Average18.50
Low17.26
Current 14.10
EPS
Actual
Estimate
0.270.530.801.06
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 357
Institutional Holdings: 97.41M
% Owned: 3.08%
Shares Outstanding: 3.16B
TypeInstitutionsShares
Increased
90
6.73M
New
29
3.29M
Decreased
98
16.42M
Sold Out
41
6.40M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.52%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Chairman/Independent Director
Masahiro Sakane
President/Chief Executive Officer/Director
Christophe Weber
Chief Financial Officer/Director
Costa Saroukos
Other/Director
Andrew Plump
Director
Masato Iwasaki
Independent Director
Olivier Bohuon
Independent Director
Jean-Luc Butel
Independent Director
Ian Clark
Independent Director
Yoshiaki Fujimori
Independent Director
Steven Gillis
Independent Director
Koji Hatsukawa
Independent Director
Emiko Higashi
Independent Director
Masami Iijima
Independent Director
Shiro Kuniya
Independent Director
Michel Orsinger
Independent Director
Toshiyuki Shiga
Declaration Date
Dividend Per Share
Ex-Div Date
03/15/2021
Dividend USD 0.340133
03/30/2021
--
Dividend USD 0.360453
09/29/2020
--
Dividend USD 0.305695
03/30/2020
--
Dividend USD 0.299617
09/27/2019
03/15/2019
Dividend USD 0.304093
03/28/2019
--
Dividend USD 0.288
09/27/2018
About TAK
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Webull offers kinds of Takeda Pharmaceutical Co Ltd (ADR) stock information, including NYSE:TAK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TAK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TAK stock methods without spending real money on the virtual paper trading platform.